This study is a 56-week, multi-center, blinded, randomized, double-masked parallel group
comparative effectiveness study of approaches to stepping down therapy for patients with
well-controlled asthma treated with combination ICS and LABA.
Phase:
Phase 4
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
American Lung Association GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance